← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	2,708	+192	+8%	$199B
2	2 Danaher DHR $158B	2,314	+164	+8%	$133B
3	3 Novartis NVS $279B	1,515	+110	+8%	$18.4B
4	4 Regeneron Pharmaceuticals REGN $80.1B	1,390	+144	+12%	$70.7B
5	5 Agilent Technologies A $49.1B	1,149	+106	+10%	$34.9B
6	6 Illumina ILMN $41B	862	+84	+11%	$20.8B
7	7 Alnylam Pharmaceuticals ALNY $30B	851	+28	+3%	$52.7B
8	8 Charles River Laboratories CRL $14.4B	583	+27	+5%	$10.6B
9	9 Revvity RVTY $17B	512	-12	-2%	$11B
10	10 Guardant Health GH $21.9B	497	+102	+26%	$13.4B
11	11 Ionis Pharmaceuticals IONS $7.1B	493	+57	+13%	$13.5B
12	12 CRISPR Therapeutics CRSP $4.86B	480	+39	+9%	$4.01B
13	13 BridgeBio Pharma BBIO $12.7B	435	+43	+11%	$14.4B
14	14 GRAIL Inc GRAL $6.24B	425	+77	+22%	$2.57B
15	15 Arrowhead Research ARWR $8.25B	401	+97	+32%	$7.71B
16	16 Bruker BRKR $8.47B	355	+15	+4%	$6.41B
17	17 PTC Therapeutics PTCT $4.98B	353	+59	+20%	$7.04B
18	18 Sarepta Therapeutics SRPT $1.78B	347	+27	+8%	$2.01B
19	19 Krystal Biotech KRYS $9.79B	334	+50	+18%	$7.01B
20	20 Veracyte VCYT $3.5B	329	+31	+10%	$3.65B
21	21 10x Genomics TXG $9.52B	323	+6	+2%	$2.01B
22	22 Qiagen QGEN $9.41B	322	-18	-5%	$6.76B
23	23 Azenta AZTA $1.63B	296	+19	+7%	$1.74B
24	24 Intellia Therapeutics NTLA $1.6B	293	+9	+3%	$938M
25	25 Ultragenyx Pharmaceutical RARE $1.47B	288	-15	-5%	$2.16B